[Oral anticoagulation in activated protein C resistance?].
Stiegler
H
H
Abteilung Internistische Angiologie, Städtisches Krankenhaus Schwabing, München.
D000925:Anticoagulants / Q000627:therapeutic use*; D001157:Arterial Occlusive Diseases / Q000188:drug therapy* / Q000601:surgery; D001241:Aspirin / Q000627:therapeutic use; D004351:Drug Resistance; D006801:Humans; D008297:Male; D008875:Middle Aged; D010644:Phenprocoumon / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011486:Protein C / Q000627:therapeutic use*; D015607:Stents; D013988:Ticlopidine / Q000627:therapeutic use
D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors; D011486:Protein C; D013988:Ticlopidine; D010644:Phenprocoumon; D001241:Aspirin